Study for the pathogenesis of eosinophilic polyangiitis granulomatosis (EGPA)
Not Applicable
- Conditions
- Eosinophilic granulomatosis with polyangiitis
- Registration Number
- JPRN-UMIN000040163
- Lead Sponsor
- ational Hospital Organization Sagamihara National Hospital
- Brief Summary
In active EGPA, 33 proteins, mainly related to eosinophils, type 2 inflammation, and cell adhesion factors, were elevated compared to asthma. In contrast, 12 proteins were decreased with steroid treatment. Fifty-nine proteins, including functional proteins involved in cell proliferation, angiogenesis, and type 3 inflammation as well as eosinophilic inflammation, were altered by the additional administration of mepolizumab. MicroRNA coverage analysis showed 8 significantly different between EGPA and asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Individuals who are judged to be ineligible by the study representative or the treating physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in microRNA Expression between EGPA and Non EGPA Cases
- Secondary Outcome Measures
Name Time Method 1. Quantitative differences in cytokines/chemokines between EGPA and non EGPA cases. 2. Differences in microRNA Expression in EGPA Cases Before (= Active stage) and After several treatment (= Stable stage) 3. Quantitative Differences in Cytokines and Chemokines in EGPA Cases Before and After several treatment